Monday, 19 October 2026European Markets

BALYO Stock Went Up By Over 33% In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of BALYO (CAC 40: BALYO.PA) rose by a staggering 33.19% in 21 sessions from $0.47 to $0.63 at 16:55 EST on Tuesday, following the last session's upward trend. CAC 40 is dropping 0.07% to $7,132.35, following the last session's downward trend.

BALYO's last close was $0.58, 54.12% under its 52-week high of $1.26.

About BALYO

Balyo SA designs, develops, and markets material handling robots worldwide. The company offers robotic pallet and reach trucks, tuggers, stackers, counterbalanced stackers, very narrow aisles, and autonomous mobile robots. Its products are used in intelligent pallet detection, barcode scanning, inter-building transport, push button configuration, machine interface, ERP interfacing, and palletizers; and WMS interface and 3D camera applications. The company serves 3PL, automotive, e-commerce, and consumer goods industries. Balyo SA was founded in 2004 and is headquartered in Arcueil, France.

Earnings Per Share

As for profitability, BALYO has a trailing twelve months EPS of $-0.081.

More news about BALYO (BALYO.PA).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com